Virtus ETF Advisers LLC Tricida, Inc. Transaction History

Virtus ETF Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$3.95 - $5.41 $152,442 - $208,788	-38,593 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $3,046 - $5,257	674 Added 1.78%	38,593 $204,000
Q4 2020 Feb 12, 2021	BUY	$4.37 - $9.46 $112,912 - $244,427	25,838 Added 213.87%	37,919 $267,000
Q3 2020 Nov 13, 2020	SELL	$8.56 - $26.93 $14,012 - $44,084	-1,637 Reduced 11.93%	12,081 $109,000
Q2 2020 Aug 05, 2020	BUY	$21.21 - $31.55 $97,862 - $145,571	4,614 Added 50.68%	13,718 $377,000
Q1 2020 May 14, 2020	SELL	$18.43 - $38.04 $24,696 - $50,973	-1,340 Reduced 12.83%	9,104 $200,000
Q4 2019 Feb 13, 2020	BUY	$29.6 - $43.71 $91,464 - $135,063	3,090 Added 42.02%	10,444 $394,000
Q3 2019 Nov 12, 2019	SELL	$29.87 - $42.22 $12,186 - $17,225	-408 Reduced 5.26%	7,354 $227,000
Q2 2019 Aug 13, 2019	SELL	$31.16 - $39.46 $26,953 - $34,132	-865 Reduced 10.03%	7,762 $306,000
Q1 2019 May 14, 2019	SELL	$19.96 - $38.62 $20,079 - $38,851	-1,006 Reduced 10.44%	8,627 $333,000
Q4 2018 Feb 05, 2019	BUY	$23.57 - $32.33 $227,049 - $311,434	9,633 New	9,633 $227,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.